Psychedelics represent a fascinating class of compounds, ranging from naturally occurring molecules such as psilocybin and mescaline to synthetic analogues like LSD. For decades, these substances were constrained by regulatory and societal stigma, leaving their therapeutic potential largely unexplored, and a scientific moratorium on research. Today, however, renewed scientific interest, driven by promising data in psychiatry, has opened the door to rigorous research aimed at understanding their mechanisms and translating them into viable treatments.
As a CDMO with a facility designed to work with highly potent compounds, we see the promise of psychedelic medicines up close, alongside the practical challenges that determine whether a programme advances on time and on budget. From controlled substance licensing to formulation strategy, the road from API to clinic (and eventually market) is navigable, but it demands deep technical rigor, robust quality systems, and early, transparent collaboration. Here’s an overview of some of the key challenges facing psychedelics, as well as their possibilities in psychiatry.
Psychedelic therapies are rapidly moving from the fringes of medicine into mainstream drug development, creating both exciting opportunities and complex challenges for biotech innovators. As the industry shifts its focus from regulatory feasibility to practical development and commercialisation, one question is becoming increasingly important: what is the most effective way to deliver these therapies to patients?
In this paper, we explore why nasal delivery is emerging as a leading platform for next-generation psychedelic medicines, offering benefits such as rapid onset, precise dosing control, improved bioavailability, and the potential to support increasingly popular psychedelic-assisted therapy models.
In this paper, you’ll discover:
- The current psychedelic drug development landscape.
- Why traditional dosage forms may not meet the needs of newer psychedelic compounds.
- The scientific and commercial drivers behind the growth of intranasal psychedelic products.
- Key formulation, manufacturing and containment challenges facing developers.
- How delivery route selection can influence both patient experience and clinical success.
We also examine the unique development considerations facing biotech companies, from controlled substance handling and HPAPI containment to scaling innovative therapies for clinical and commercial supply.
Nasal Delivery of Psychedelics: Next Generation Delivery Options
Download the full paper to learn why nasal delivery is becoming one of the most promising approaches for psychedelic drug development, and what developers should consider when bringing these therapies to their CDMO.